| Dokumentenart: | Artikel | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Titel eines Journals oder einer Zeitschrift: | Oncology | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Verlag: | KARGER | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ort der Veröffentlichung: | BASEL | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Band: | 73 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Nummer des Zeitschriftenheftes oder des Kapitels: | 1-2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Seitenbereich: | S. 21-25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Datum: | 2007 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Institutionen: | Medizin > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) Medizin > Lehrstuhl für Neurologie | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Identifikationsnummer: |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Klassifikation: |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stichwörter / Keywords: | ACTIVATED-RECEPTOR-GAMMA; GLIOBLASTOMA-MULTIFORME; PROGNOSTIC-SIGNIFICANCE; MALIGNANT GLIOMA; CLINICAL-TRIALS; CYCLOOXYGENASE-2; EXPRESSION; APOPTOSIS; CANCER; GROWTH; glioblastoma; anaplastic glioma; low-dose chemotherapy; drug resistance; capecitabine; temozolomide; pioglitazone; rofecoxib | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Dewey-Dezimal-Klassifikation: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Status: | Veröffentlicht | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Begutachtet: | Ja, diese Version wurde begutachtet | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| An der Universität Regensburg entstanden: | Unbekannt / Keine Angabe | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Dokumenten-ID: | 29320 |
Web of ScienceZusammenfassung
Objectives: Combined treatment approaches targeting tumor as well as other cells contributing to tumor progression may control chemorefractory malignancies. Methods: A phase II trial was initiated to analyze the activity of continuously administered pioglitazone and rofecoxib combined with low-dose chemotherapy ( capecitabine or temozolomide) in patients with high-grade gliomas ( glioblastoma or ...
Zusammenfassung
Objectives: Combined treatment approaches targeting tumor as well as other cells contributing to tumor progression may control chemorefractory malignancies. Methods: A phase II trial was initiated to analyze the activity of continuously administered pioglitazone and rofecoxib combined with low-dose chemotherapy ( capecitabine or temozolomide) in patients with high-grade gliomas ( glioblastoma or anaplastic glioma). Results: Fourteen patients were evaluable for response and toxicity. Major side effects were palmoplantar erythema, edema and motor neuropathy grade 3. Disease stabilizations lasting longer than 3 months were noted in 4 of 14 patients ( 29%). Clinical responses did not correspond to immunohistochemical staining for cyclooxygenase 2, peroxisome proliferator-activated receptor- gamma and CD31. Discussion: The study demonstrates that this novel regimen is moderately active and well tolerated in patients with high-grade gliomas. As a comparably small proportion of patients responded, the regimen might only be suitable for a subset of highly selected patients. Copyright (c) 2008 S. Karger AG, Basel.
Metadaten zuletzt geändert: 29 Sep 2021 07:39
Altmetric